Labels
Breast Cancers
(147)
Genitourinary Cancers
(73)
Lung Cancers
(73)
Gastrointestinal Cancers
(67)
Gynecological Cancers
(56)
Head and Neck Cancers
(50)
Cutaneous Cancers
(21)
Central Nervous System Cancers
(11)
Tuesday, 29 April 2014
EMA recommends granting a marketing authorisation for trametinib and extending indications for sorafenib
The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorisation for trametinib (Mekinist) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. The CHMP has also recommended adding a new indication to the use of the cancer medicine sorafenib (Nexavar) to treat patients with papillary/follicular/Hürthle cell thyroid carcinoma, refractory to radioactive iodine. Read more here.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment